Condition: Central Nervous System Lymphoma · Sponsor: Tong Chen, MD
This is a single-arm and open-label study to explore X+MTX+Ritu (ATG-010, Methotrexate, Rituximab) regimen in Relapse refractory PCNSL patients. Approximately 30 patients will be enrolled in the study. In dose escalation phase, patients with Relapse refractory PCNSL will be treated with X+MTX+Ritu regimen and escalating doses of oral ATG-010 weekly in a 3+3 design. Then a phase 2 expansion at the recommended dose level based on phase 1b trial will be conducted to evaluate the efficacy, safety and tolerability.
This description comes directly from the study's public registry record.
Tong Chen, Ph.D · +862152887102 · chentong@fudan.edu.cn
Yuan Yan, Ph.D · +862152888283 · yuanyan@fudan.edu.cn
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital Of Anhui Medical University | Hefei, Anhui, China | Not Yet Recruiting |
| Beijing Tiantan Hospital, Capital Medical University | Beijing, Beijing Municipality, China | Not Yet Recruiting |
| The First Affiliated Hospital Of Fujian Medical University | Fuzhou, Fujian, China | Not Yet Recruiting |
| Oncology Department of The First Affiliated Hospital of Zhengzhou University | Zhengzhou, Henan, China | Not Yet Recruiting |
| Department of Hematology, Huashan Hospital, Fudan University | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05698147